The addition of empagliflozin to insulin therapy reduces glycated hemoglobin levels in patients with type 1 diabetes, indicate findings from the phase III EASE-2 and 3 trials.
Almost half of young adults with type 1 diabetes do not see a diabetes physician for more than a year during their transition from pediatric to adult care, and this lack of contact is associated with an increased risk for complications, Canadian research shows.
Continuous subcutaneous insulin infusion therapy significantly lowers glycated hemoglobin levels in young people with type 1 diabetes, but at the cost of an increased risk for diabetic ketoacidosis during the first year, UK researchers report.
Editorial Board member and Endocrinologist, Sanjay Kalra comments on the issues raised by a clinical case involving sodium glucose cotransporter 2 inhibitor therapy alongside a restrictive diet.
Editorial board member John Wilding casts a critical eye over the positive buzz surrounding the potential uses of sodium-glucose cotransporter 2 inhibitors in type 1 diabetes treatment.
medwireNews outlines which medications have so far been tested as adjunct treatments for type 1 diabetes and summarizes the key trial data showing their benefits or otherwise.